An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit
NCT04388072 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2022-02-03
Summary
The diagnostic cohort study could will be use to verify the clinical performance of the AQP4 -immunoglobulin G detection kit and whether it has a good correlation with the clinical diagnosis results. The applicability and accuracy of the kit in clinical diagnosis will be verified according to the measured data.
Conditions
- Neuromyelitis Optica Spectrum Disorders
Sponsors & Collaborators
-
MyBiotech Co. Ltd, China
collaborator UNKNOWN -
Third Affiliated Hospital, Sun Yat-Sen University
collaborator OTHER -
First Affiliated Hospital of Fujian Medical University
lead OTHER
Eligibility
- Min Age
- 14 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-05-15
- Primary Completion
- 2020-12-01
- Completion
- 2021-02-20
Countries
- China
Study Locations
More Related Trials
-
Anti-Argonaute Antibodies for the Diagnosis of Sensory Neuronopathies
NCT05966350 ·Status: COMPLETED
-
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
NCT03350633 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Ofatumumab in AQP4-IgG Seropositive NMOSD
NCT05504694 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
NCT05145361 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Inectolizumab With Steroid Optimization in Newly Treated NMOSD
NCT07159893 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
NCT04535843 ·Status: RECRUITING
-
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
NCT01845584 ·Status: COMPLETED ·Phase: PHASE2
-
Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
NCT04356781 ·Status: COMPLETED
-
National, Multicentric Registry Study on Neuroimmunological Diseases in China
NCT06443333 ·Status: RECRUITING
-
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
NCT06044350 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Registered Cohort Study of Immune-Mediated Neuropathies
NCT04292834 ·Status: UNKNOWN
-
Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder
NCT07032337 ·Status: COMPLETED
-
Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy
NCT07121985 ·Status: NOT_YET_RECRUITING
-
Meningococcal Vaccination in Patients on Complement Inhibitors
NCT06906692 ·Status: ACTIVE_NOT_RECRUITING
-
Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
NCT06844864 ·Status: ACTIVE_NOT_RECRUITING
-
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
NCT07021209 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
NCT03330418 ·Status: TERMINATED ·Phase: PHASE3
-
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
NCT03864185 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Two Cell-based Assays for Diagnosing MOG-IgG Associated Disorders
NCT06617962 ·Status: RECRUITING
-
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
NCT04182984 ·Status: RECRUITING
-
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
NCT05728684 ·Status: UNKNOWN ·Phase: NA
-
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832 ·Status: RECRUITING
-
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT04881682 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
NCT05403138 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
GC012F in Patients With Autoimmune Diseases
NCT07072884 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1